Company
Noninvasix
Noninvasix is expected to be the first company to non-invasively monitor central venous oxygenation, an indicator of the severity of sepsis and septic shock, enabling clinicians to diagnose and monitor the response to treatment of tissue hypoxia in real-time.
Also known as Noninvasix, Inc.
- Status
- Operatingas of 2026-09-18
- Business model
- B2B
- Customers
- clinicians
- Legal name
- Noninvasix, Inc.
- noninvasix.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- X (opens in a new tab)
- Press page (opens in a new tab)
Claim, correct or request removal
Record updated 28 September 2026
About
Noninvasix’s patented optoacoustic platform technology is the first solution designed to non-invasively and continuously measure central venous saturation.
Funding snapshot
- Total raised
- $4MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $4M2020-03-17
Funding rounds
- Round, 2020
- $4M2020-03-17, SEC form D sold, 18 investors
Products
- Hardware
- optoacoustic platform technology
Loading relationship preview